

Document made available under the Patent Cooperation Treaty (PCT)

International application number: PCT/SE05/000499

International filing date: 06 April 2005 (06.04.2005)

Document type: Certified copy of priority document

Document details: Country/Office: SE
Number: 0400968-4
Filing date: 14 April 2004 (14.04.2004)

Date of receipt at the International Bureau: 02 May 2005 (02.05.2005)

Remark: Priority document submitted or transmitted to the International Bureau in compliance with Rule 17.1(a) or (b)



World Intellectual Property Organization (WIPO) - Geneva, Switzerland
Organisation Mondiale de la Propriété Intellectuelle (OMPI) - Genève, Suisse

PRV

PATENT- OCH REGISTRERINGSVERKET
Patentavdelningen

PCT / SE 2005 / 000499

Intyg Certificate

Härmed intygas att bifogade kopior överensstämmer med de handlingar som ursprungligen ingivits till Patent- och registreringsverket i nedannämnda ansökan.

Ansökan ingavs ursprungligen på engelska.

This is to certify that the annexed is a true copy of the documents as originally filed with the Patent- and Registration Office in connection with the following patent application.

The application was originally filed in English.


(71) Sökande AstraZeneca AB, Södertälje SE
Applicant (s)

(21) Patentansökningsnummer 0400968-4
Patent application number

(86) Ingivningsdatum 2004-04-14
Date of filing

Stockholm, 2005-04-12

För Patent- och registreringsverket
For the Patent- and Registration Office


Görel Gustafsson
Avgift
Fee

PATENT- OCH
REGISTRERINGSVERKET
SWEDEN

Postadress/Adress
Box 5055
S-102 42 STOCKHOLM

Telefon/Phone
+46 8 782 25 00
Vx 08-782 25 00

Telex
17978
PATOREG S

Telefax
+46 8 666 02 86
08-666 02 86

ARYL GLYCINE ETHER DERIVATIVES AND THEIR USE**FIELD OF THE INVENTION**

This invention relates to the treatment of diseases in which serotonin, Substance P or
5 Neurokinin A are implicated, for example, in the treatment of disorders or conditions such as
hypertension, depression, generalized anxiety disorder, phobias, posttraumatic stress syndrome,
avoidant personality disorder, premature ejaculation, eating disorders, obesity, chemical
dependencies, cluster headache, migraine, pain, Alzheimer's disease, obsessive-compulsive
disorder, panic disorder, memory disorders, Parkinson's disease, endocrine disorders vasospasm,
10 cerebellar ataxia, gastrointestinal tract disorders, negative symptoms of schizophrenia,
premenstrual syndrome, fibromyalgia syndrome, stress incontinence, Tourette's syndrome,
trichotillomania, kleptomania, male impotence, attention deficit hyperactivity disorder, chronic
paroxysmal hemicrania and headache.

BACKGROUND

15 The mammalian neurokinins are peptide neurotransmitters found in the peripheral and
central nervous systems. The three principal neurokinins are Substance P (SP), Neurokinin A
(NKA) and Neurokinin B (NKB). N-terminally extended forms of at least NKA are known.
Three receptor types are known for the principal neurokinins. Based upon their relative
selectivities for the neurokinins SP, NKA and NKB, the receptors are classified as neurokinin 1
20 (NK₁), neurokinin 2 (NK₂) and neurokinin 3 (NK₃) receptors, respectively. In the periphery, SP
and NKA are localized in C-afferent sensory neurons, which neurons are characterized by non-
myelinated nerve endings known as C-fibers, and are released by selective depolarization of these
neurons, or selective stimulation of the C-fibers. C-Fibers are located in the airway epithelium,
and the tachykinins are known to cause profound effects which clearly parallel many of the
25 symptoms observed in asthmatics. The effects of release or introduction of tachykinins in
mammalian airways include bronchoconstriction, increased microvascular permeability,
vasodilation, increased mucus secretion and activation of mast cells. Neurokinin antagonists that
interact with NK₁, NK₂ and NK₃ receptors, having different chemical structures have been
described. Particularly international publications WO 98/07722, WO 96/39383 and WO
30 98/25617, and regional publications EP 428434, EP 474561, EP 515240 and EP 559538 disclose
the preparation of a variety of chemical structures.


NK₁ activity is also implicated in depression and anxiety, mice with genetically altered NK₁ receptors have decreased anxiety related behavior (Santarelli, L., *et. al.*, Proc. Nat. Acad. Sci. (2001), 98, 1912) and NK₁ antagonists have been reported to be effective in an animal model of depression (Papp, M., *et. al.*, Behav. Brain Res. (2000), 115, 19).

5 Selective Serotonin Reuptake Inhibitors (SSRIs) are widely used for the treatment of major depressive disorder (MDD) and are considered well-tolerated and easily administered. SSRIs, however, have a delayed onset of action, are associated with undesirable side effects, such sexual dysfunction, and are ineffective in perhaps 30% of patients (M. J. Gitlin, MJ, J. Clin. Psych., 55, 406-413, 1994).

10 Compounds with dual action as NK₁ antagonists and serotonin reuptake inhibitors may also provide a new class of antidepressants. Indeed, compounds combining NK₁ antagonism and serotonin reuptake inhibition have been described (Ryckmans, T., *et. al.*, Bioorg. Med. Chem. Lett. (2002), 12, 261).

SUMMARY OF THE INVENTION

15 The present invention encompasses compounds having neurokinin 1 ("NK₁") antagonist activity and/or serotonin reuptake inhibitory ("SRI") activity. Aryl glycine compounds of the invention are those on accord with formula I



I

20 wherein:

R¹ and R² are independently selected from C₁₋₆ alkyl or C₁₋₆ alkenyl, or together with the N to which they are bound, form a heterocycle containing 6-8 atoms or heterocycle substituted with moieties independently selected from hydrogen, halogen, C₁₋₄ alkyl, C₁₋₄ alkoxy or C₁₋₄ alkyl substituted with 1, 2 or 3 halo moieties, amino, or amino substituted with C₁₋₄ alkyl, C₁₋₄ alkoxy or C₁₋₄ alkyl, substituted with 0, 1, 2, or 3 halo moieties; in vivo-hydrolysable precursors thereof, and pharmaceutically-acceptable salts thereof;

R³ and R⁴ are independently selected from hydrogen or C₁₋₆ alkyl;

101431

2004-04-11

- 3 -

n is 0, 1 or 2;

Ar¹ is phenyl or phenyl substituted with moieties independently selected from hydrogen, halogen, C₁₋₄ alkyl, C₁₋₄ alkoxy or C₁₋₄ alkyl substituted with 1, 2 or 3 halo moieties; in vivo-hydrolysable precursors thereof, and pharmaceutically-acceptable salts thereof; and


5 Ar² phenyl, naphthyl, tetralin, or phenyl, naphthyl or tetralin substituted with moieties independently selected from hydrogen, halogen, cyano, nitro, C₁₋₄ alkyl, C₁₋₄ alkoxy or C₁₋₄ alkyl substituted with 1, 2 or 3 halo moieties; in vivo-hydrolysable precursors thereof, and pharmaceutically-acceptable salts thereof.

The invention also encompasses in vivo-hydrolysable precursors and pharmaceutically-acceptable salts of the compounds, pharmaceutical compositions and formulations containing
10 them, methods of using them to treat diseases and conditions either alone or in combination with other therapeutically-active compounds or substances, processes and intermediates used to prepare them, uses of them as medicaments, uses of them in the manufacture of medicaments and uses of them for diagnostic and analytic purposes.

15 DETAILED DESCRIPTION OF THE INVENTION

Compounds of this invention have NK₁ antagonist activity and/or SRI activity. Accordingly, this invention comprises such compounds, pharmaceutical compositions containing such compounds and methods of using such compounds to treat central nervous system (CNS) and other disorders.

20 Compounds of the invention are those in accord with formula I:



I

wherein:

25 R¹ and R² are independently selected from C₁₋₆ alkyl or C₁₋₆ alkenyl, or together with the N to which they are bound, form a heterocycle containing 6-8 atoms or heterocycle substituted with moieties independently selected from hydrogen, halogen, C₁₋₄ alkyl, C₁₋₄ alkoxy or C₁₋₄ alkyl substituted with 1, 2 or 3 halo moieties, amino, or amino substituted with C₁₋₄ alkyl, C₁₋₄ alkoxy

or C₁₋₄ alkyl, substituted with 0, 1, 2, or 3 halo moieties; in vivo-hydrolysable precursors thereof, and pharmaceutically-acceptable salts thereof;

R³ and R⁴ are independently selected from hydrogen or C₁₋₆ alkyl;

n is 0, 1 or 2;

5 Ar¹ is phenyl or phenyl substituted with moieties independently selected from hydrogen, halogen, C₁₋₄ alkyl, C₁₋₄ alkoxy or C₁₋₄ alkyl substituted with 1, 2 or 3 halo moieties; in vivo-hydrolysable precursors thereof, and pharmaceutically-acceptable salts thereof; and

Ar² phenyl, naphthyl, tetralin, or phenyl, naphthyl or tetralin substituted with moieties independently selected from hydrogen, halogen, cyano, nitro, C₁₋₄ alkyl, C₁₋₄ alkoxy or C₁₋₄ alkyl
10 substituted with 1, 2 or 3 halo moieties; in vivo-hydrolysable precursors thereof, and pharmaceutically-acceptable salts thereof.

Particular compounds of the invention are those of the examples herein.

Another aspect of the invention is pharmaceutically-acceptable salts of a compounds as described herein made with an inorganic or organic acid which affords a physiologically-
15 acceptable anion.

Particular pharmaceutically-acceptable salts of compounds of the invention are those wherein the inorganic or organic acid is selected from hydrochloric, hydrobromic, sulfuric, phosphoric, methanesulfonic, sulfamic, para-toluenesulfonic, acetic, citric, lactic, tartaric, malonic, fumaric, ethanesulfonic, benzenesulfonic, cyclohexylsulfamic, salicylic and quinic
20 acids.

Another aspect of the invention is a pharmaceutical composition comprising a compound of the invention or an in vivo-hydrolysable precursor or a pharmaceutically-acceptable salt thereof and a pharmaceutically-acceptable carrier.

Yet another aspect of the invention is a method of treating a disease condition wherein
25 antagonism of NK₁ receptors and/or SRI activity is beneficial which method comprises administering to a warm-blooded animal an effective amount of a compound of the invention or an in vivo-hydrolysable precursor or a pharmaceutically-acceptable salt thereof.

Still another aspect of the invention is the use of a compound of the invention or an in vivo-hydrolysable precursor or a pharmaceutically-acceptable salt thereof in the preparation of a
30 medicament for use in a disease condition wherein antagonism of the NK₁ receptors and/or SRI activity is beneficial.

A further aspect of the invention is a method for treating a disorder or condition selected from hypertension, depression in cancer patients, depression in Parkinson's patients, postmyocardial infarction depression, subsyndromal symptomatic depression, depression in infertile women, pediatric depression, major depression, single episode depression, recurrent
5 depression, child abuse induced depression, post partum depression, generalized anxiety disorder, agoraphobia, social phobia, simple phobias, posttraumatic stress syndrome, avoidant personality disorder, premature ejaculation, anorexia nervosa, bulimia nervosa, obesity, addictions to alcohol, cocaine, heroin, phenobarbital, nicotine or benzodiazepines; cluster headache, migraine, pain, Alzheimer's disease, obsessive-compulsive disorder, panic disorder, dementia, amnesic
10 disorders, age-related cognitive decline, dementia in Parkinson's disease, neuroleptic-induced parkinsonism, tardive dyskinesias, hyperprolactinaemia, vasospasm, cerebral vasculature vasospasm, cerebellar ataxia, gastrointestinal tract disorders, negative symptoms of schizophrenia, premenstrual syndrome, fibromyalgia syndrome, stress incontinence; Tourette's syndrome, trichotillomania, kleptomania, male impotence, attention deficit hyperactivity
15 disorder, chronic paroxysmal hemicrania and headache associated with vascular disorders in a mammal, wherein antagonism of the NK₁ receptors and/or SRI activity is beneficial, comprising administering an effective amount of a compound of the invention or a pharmaceutically-acceptable salt thereof effective in treating such disorder or condition.

In a particular aspect of the invention the method for treating a disorder or condition
20 mentioned herein, comprises administering a compound of the invention in combination with a pharmaceutically-acceptable carrier.

Compounds in accord with formula I and their in vivo-hydrolysable precursors or a pharmaceutically-acceptable salts may be made by processes as described and exemplified herein and by processes similar thereto and by processes known in the chemical art. If not commercially
25 available, starting materials for these processes may be made by procedures which are selected from the chemical art using techniques which are similar or analogous to the synthesis of known compounds.

Pharmaceutically-acceptable salts may be prepared from the corresponding acid in a conventional manner. Non-pharmaceutically-acceptable salts may be useful as intermediates and
30 as such are another aspect of the present invention.

It is well known in the art how to prepare optically-active forms (for example, by resolution of the racemic form or by synthesis from optically-active starting materials) and all optically active forms, enantiomers are compounds of this invention. Further, the mixture of enantiomers can have either or both serotonin and neurokinin activity and/or either of the pure enantiomers can have serotonin and or neurokinin activity.

The following biological test methods, data and Examples serve to illustrate and further describe the invention.

The utility of a compound of the invention or an in vivo-hydrolysable precursor or a pharmaceutically-acceptable salt thereof (hereinafter, collectively referred to as a "Compound") may be demonstrated by standard tests and clinical studies, including those disclosed in the publications described below.

Biological Assays:

Test A — SERT Binding Assay:

Frozen membrane preparations of a stably transfected HEK293 cell line expressing human 5-HTT receptors were purchased from Receptor Biology (PerkinElmer). Frozen aliquots were rapidly thawed, homogenized, and diluted in assay buffer (AB) containing 50 mM TRIS-HCL, 120 mM NaCl, 5 mM KCl and adjusted to pH 7.4 with NaOH. Final protein concentration was 40 µg/ml. Test compounds were evaluated in competition assays utilizing [³H]-Imipramine Hydrochloride purchased from NEN (PerkinElmer) as the radioligand. The stock radioligand was diluted with AB for a final concentration of approximately 2 nM. K_d for [³H]-Imipramine Hydrochloride was determined to be 2.7 nM. The competition assays were performed on 96-well assay plates — two drugs per plate. Ten serial dilutions (normally 1 µM to 38 pM final concentration) from stock 10 mM solutions of compounds prepared in DMSO. All serial dilutions were made using 20% DMSO. DMSO content in assay is less than 1%. Incubation mixtures were prepared in quadruplicate in 96-well plates (Costar). Final assay volumes per well were 10 µl compound/nonspecific/control (1% DMSO), 20 µl membranes, 20 µl [³H]-Imipramine Hydrochloride, and 150 µl AB. Specific binding was defined by using 10 µM Imipramine. The binding reaction was initiated by adding membranes immediately after adding the radioligand to wells containing buffer plus either test compound, nonspecific, or control. The assay plates were placed on a plate shaker and shaken for thirty min while the reactions reached equilibrium. The plates were then filtered through Beckman GF/B filters, presoaked in 6% PEI, using a Packard

101431

2004-04-14

- 7 -

Filtermate 196. Filters were washed 5x with 0.2 ml ice-cold wash buffer (5 mM Tris HCl, pH 7.4.) The filters were dried and 35 µl of Microscint20 (Packard) was added to each well. The plates were then counted on a Packard TopCount to determine CPM's per well. Ki values were determined for each test compound utilizing the graphic and analytical software package,

5 GraphPad Prism.

Test B — NK₁ FLIPR Assay using Fluo-4 Dye:

FLIPR assays are performed with a device marketed by Molecular Devices, Inc., designed to precisely measure cellular fluorescence in a high throughput whole-cell assay. (Schroeder et. al., J. Biomolecular Screening, 1(2), p 75-80, 1996).

10 Compounds were evaluated for potency in blocking the response of U373 cells to the NK₁ receptor agonist Acetyl-[Arg⁶, Sar⁹, Met(O₂)¹¹]-Substance P (ASMSP) using a FLIPR instrument.

U373 cells were loaded with Fluo-4 dye (Molecular Probes) for 45 min at 37 °C and exposed to graded concentrations of compounds for 15 min at room temperature before being challenged with 10 nM – 12 nM ASMSP (an approximately EC₈₀ concentration). Responses
15 were measured as the peak relative fluorescence after agonist addition. pIC₅₀s were calculated from eleven-point concentration-response curves for each compound.

Reagents:

Cell culture medium:

Eagle's MEM with Earle's salts and l-glutamine (500 mL)	Cellgro 10-010-CV
20 Non-essential amino acids, 100 x (5 mL)	Cellgro 25-025-CI
Sodium pyruvate, 100 mM (5 mL)	Cellgro 25-000-CI
L-Glutamine, 200 mM (5 mL)	Cellgro 25-005-CI
FBS (50 mL)	Cellgro 35-010-CV

Cell harvesting reagents:

25 DPBS, 1x without Ca ⁺⁺ & Mg ⁺⁺	Cellgro 21-031-CV
1x Trypsin -EDTA (0.5% Trypsin, 0.53% EDTA-4Na)	Cellgro 25-052-CI

Cell plating medium:

UltraCULTURE	BioWhittaker 12-725F
L-Glutamine, 200 mM (5 mL/500 mL)	Cellgro 25-005-CI

30 Working buffer:

10x Hank's balanced salt solution (100 mL/L)	Gibco 14065-056
--	-----------------

101431

2004-04-14

- 8 -

HEPES buffer 1 M (15 mL/L, [final] 15 mM)

Cellgro 25-060-CI

Probenecid (0.71 g dissolved in 6 mL 1 M NaOH for 1 L,
[final] 2.5 mM)

Sigma P-8761

DDH₂O to 1 L, adjust pH to 7.4 with NaOH5 Dye solution:

Fluo-4, AM dye, Molecular Probes F-14201. 50 µg lyophilized dye is dissolved in 23 µL DMSO plus 23 µL Pluronic F-127 (Molecular Probes P-3000). The 46 µL of solubilized fluo-4 dye is then added to 10 mL of working buffer solution to provide a working dye concentration of 5 µM. Each 10 mL of diluted dye is sufficient for a 384-well-plate of cells at 25 µL per well.

10 Agonist:Acetyl-[Arg⁶, Sar⁹, Met(O₂)¹¹]-Substance P (ASMSP)Stock solution of 3.33x10⁻² M. Dissolve 100 mg in 3.05 mL DMSO and store in aliquots at 4 °CMiscellaneous:

DMSO (to dissolve compounds and for tip wash)

15 Cell culture and plating procedures:

U373 cells were grown in cell culture medium described above (30 mL per T-150 flask) and harvested when confluent as follows. Medium was removed by aspiration and cells were washed 1x with 12 mL DPBS, without Ca⁺⁺ and Mg⁺⁺. The DPBS was aspirated and replaced with 3 mL trypsin EDTA. The cells plus trypsin/EDTA were incubated about 2 min at room temperature, until the cells detached from the flask. The harvesting reaction was quenched by addition of 9 mL culture medium and cells were resuspended by trituration.

Cells were passaged at a transfer density of 1:4 every four days. For experiments, cells were counted, pelleted by centrifugation at 400 x g for 5 min and resuspended in cell plating medium at a density of 480,000 cells/mL. 25 µL of this cell suspension was added to each well of a black-walled 384-well plate (Falcon Microtest, 35 3962) using a Labsystems Multidrop 384 to give 12,000 cells per well. Plates were incubated at 37 °C overnight (minimum 15 h, maximum 23 h) before use.

Compound and agonist preparation:

Compounds were dissolved in DMSO at a concentration of 10 mM and 120 µL of these solutions were transferred to the first well (column 1) of each row of a 96-well, round-bottomed, polypropylene storage plate (Costar 3365). Compounds on two such plates were then serially

101431

2004 -04- 14

- 9 -

diluted simultaneously in DMSO using a Biomek 2000. 4 μL of each dilution was transferred to a deep well plate (Beckman Coulter 267006) which had been prepared previously to contain 400 μL of freshly made working buffer in each well. Concentrations resulting from this procedure are shown in Table 1. The final compound concentrations in the assay span 11 points, between 10 μM and 0.1 nM, in half-log increments.

The contents of the wells were mixed, and 45 μL of each dilution were transferred - in duplicate - to a 384-well polypropylene compound loading plate (Fisher 12-565-507) so that the 384-well plate contained duplicates of each of the compounds from both 96-well plates over the concentration ranges. Columns 23 and 24 of the plate contain no compound and serve as controls. Wells A - N in columns 23 and 24 were loaded with agonist only and therefore represent the maximal response. Wells O - P in columns 23 and 24 were loaded with only buffer, no agonist, and therefore represent the minimum response.

An ASMSP agonist loading plate was made by taking stock concentration of ASMSP and diluting in working buffer to give a concentration of 3.3×10^{-8} M. 45 μL of this solution were transferred to all wells of a 384-well polypropylene agonist loading plate (Fisher 12-565-507) except wells O23, O24, P23 & P24 which contained buffer alone and served as unstimulated controls.

Dye Loading cells and adding compound:

For each 384-well assay plate of cells, 10 mL of diluted Fluo-4 dye was prepared as stated above in the methods/reagents section. First, each 384-well cell plate was washed once with working buffer on a CCS Packard plate washer. Any remaining post-wash buffer in the wells was removed by hand and 25 μL per well of Fluo-4 dye was added using a Labsystems Multidrop 384. The cell plate was returned to a 37 $^{\circ}\text{C}$ incubator for 45 min to allow the dye to permeate the cells. After 45 min of dye loading, the cell plates were washed twice with working buffer, leaving a 30 μL volume of buffer in each well. 5 μL of compound dilutions were transferred from the compound plate to the cell plate using a PlateMate. Assay plates were incubated in the presence of compound for 15 min at room temperature in the dark, and then loaded onto FLIPR.

Recording responses in FLIPR:

After the 15 min compound pre-incubation, the plates were loaded onto the FLIPR instrument, 15 μL of ASMSP agonist was added and the cellular response to the agonist was

101431

2004 -04- 1 4

- 10 -

recorded for 90 seconds. The response is measured as the peak relative fluorescence after agonist addition.

Data analysis:

Results contained in the .stat files generated by FLIPR were pasted into an Excel analysis template and, after outliers were excluded, IC₅₀ values were calculated within the template using XLfit. Individual IC₅₀ values were reported, along with pIC₅₀. When the two IC₅₀'s obtained for a compound differed by more than 3-fold that compound was assayed one or two more times to re-determine the value.

Results:

Ki values obtained in the SERT assay for compounds of the invention ranged from less than 2 nM to about 180 nM. IC₅₀ values obtained in the FLIPR assay for compounds of the invention ranged from about 70 nM to about 2 µM.

Examples:

The invention is illustrated by, but not limited to, the following examples in which descriptions, where applicable and unless otherwise stated, the following terms, abbreviations and conditions are used:

aq., aqueous; atm, atmospheric pressure; BOC, 1,1-dimethylethoxycarbonyl, ACN, acetonitrile; DCM, dichloromethane; DMR, N,N-dimethylformamide; DMSO, dimethyl sulfoxide; EtOH, ethanol; Et₂O, diethyl ether; EtOAc, ethyl acetate; h, hour(s); HPLC, high performance liquid chromatography; HOBT, 1-hydroxybenzotriazole; MeOH, methanol; min, minutes; MS, mass spectrum; NMR, nuclear magnetic resonance; psi, pounds per square inch; RT, room temperature; sat., saturated; TEA, triethylamine; TFA, trifluoroacetic acid; THF, tetrahydrofuran.

Temperatures are given in degrees Celsius (°C); unless otherwise stated, operations were carried out at room or ambient temperature (18-25 °C).

Organic solutions were dried over anhydrous sodium or magnesium sulfate; evaporation of solvent was carried out using a rotary evaporator under reduced pressure (4.5-30 mm Hg) with a bath temperature of up to 60 °C.

Chromatography means flash column chromatography on silica gel unless otherwise noted; solvent mixture compositions are given as volume percentages or volume ratios.

101431

2004-04-14

- 11 -

When given, NMR data is in the form of delta values for major diagnostic protons (given in parts per million (ppm) relative to tetramethylsilane as an internal standard) determined at 300 MHz.

Melting points are uncorrected.

- 5 Mass spectra (MS) were obtained using an automated system with atm chemical ionization (APCI) unless otherwise indicated. Masses corresponding to the major isotopic component, or the lowest mass for compounds with multiple masses with nearly equivalent abundance (isotope splitting), are reported.

- 10 Where noted that a final compound was converted to the citrate salt, the free base was dissolved in MeOH, DCM, or ACN, combined with citric acid (1.0 equivalents) in MeOH, concentrated under reduced pressure and dried under vacuum (25-60 °C). When indicated that the salt was isolated by filtration from Et₂O, the citrate salt of the compound was stirred in Et₂O for 4-18 h, recovered by filtration, washed with Et₂O, and dried under vacuum (25-60 °C).

- 15 **Example 1:** 4-{[2-(3-Chloro-4-fluorophenyl)-2-piperazin-1-ylethoxy]methyl}-3-methoxy-2-naphthonitrile.

- tert*-Butyl 4-{1-(3-chloro-4-fluorophenyl)-2-[(3-cyano-2-methoxy-1-naphthyl)methoxy]ethyl}piperazine-1-carboxylate (100 mg, 0.18 mmol) was dissolved in DCM (2 mL) and TFA (2 mL) was added. After 2h the volatiles were removed under reduced pressure. The residue was taken up in EtOAc (20 mL) and washed with sat. aq. NaHCO₃ (20 mL). The organic phase was dried over Na₂SO₄, filtered through a pad of diatomaceous earth and the volatiles removed under reduce pressure. Chromatography of the residue on SiO₂ (0-5% 2 M NH₃ in MeOH:DCM) afforded the title compound as an off-white solid (81.6 mg, 79%). The citrate salt was formed by the addition of citric acid (1.0 equivalents) to a methanolic solution of the title compound. Concentration under reduced pressure afforded the desired salt form of the product as an off-white powder. MS m/z 454.4 (M+H)⁺. ¹H NMR (300.1 MHz, DMSO + TFA) δ 8.64 (s, 1H), 8.08 (t, *J* = 7.6 Hz, 2H), 7.80 (dd, *J* = 1.9, 7.1 Hz, 1H), 7.72 (t, *J* = 7.1 Hz, 1H), 7.64 (t, *J* = 7.6 Hz, 1H), 7.55 - 7.45 (m, 2H), 5.06 (dd, *J* = 15.4, 11.0 Hz, 2H), 4.78 (t, *J* = 5.0 Hz, 1H), 4.20 (d, *J* = 5.0 Hz, 2H), 3.99 (s, 3H), 3.41 - 3.34 (m, 6H), 3.23 - 3.19 (m, 2H), 2.75 (dd, *J* = 33.0, 15.4 Hz, 4H), 1.83 (s, 1H).
- 30 The requisite *tert*-butyl 4-{1-(3-chloro-4-fluorophenyl)-2-[(3-cyano-2-methoxy-1-naphthyl)methoxy]ethyl}piperazine-1-carboxylate was synthesized using the following method.

tert-Butyl 4-[1-(3-chloro-4-fluorophenyl)-2-hydroxyethyl]piperazine-1-carboxylate (65 mg, 0.18 mmol) was dissolved in THF (1.8 mL). 4-(Iodomethyl)-3-methoxy-2-naphthonitrile (70 mg, 0.22 mmol) was added followed by NaH (9 mg, 0.36 mmol). After reacting at RT overnight, water (60 mL) was added. The mixture was extracted with EtOAc (40 mL). The organic phase
 5 was dried over Na₂SO₄, filtered through a pad of diatomaceous earth and the volatiles removed under reduce pressure. Chromatography of the residue on SiO₂ (0-30% EtOAc:hexane) afforded the title compound (99 mg). MS *m/z* 554.6 (M+H)⁺.

The requisite *tert*-butyl 4-[1-(3-chloro-4-fluorophenyl)-2-hydroxyethyl]piperazine-1-carboxylate was synthesized using the following method.

10 Borane-methyl sulfide complex (2M in THF, 1.07 mL) was added to a solution of [4-(*tert*-butoxycarbonyl)piperazin-1-yl](3-chloro-4-fluorophenyl)acetic acid (200 mg, 0.54 mmol) in THF (3 mL). After 30 min at RT the reaction was heated to reflux for 4h. After cooling the reaction to RT, MeOH (10 mL) was slowly added. After stirring overnight the volatiles were
 15 removed under reduced pressure. Chromatography of the residue on SiO₂ (0-50% EtOAc:hexane) afforded the title compound (160 mg, 83%). MS *m/z* 359.3 (M+H)⁺, 303.2 (M+H-*t*-butyl).

The requisite [4-(*tert*-butoxycarbonyl)piperazin-1-yl](3-chloro-4-fluorophenyl)acetic acid was synthesized using the following method.

(3-Chloro-4-fluorophenyl)boronic acid (440 mg, 2.52 mmol), *tert*-butyl piperazine-1-carboxylate (469 mg, 2.52 mmol) and glyoxylic acid monohydrate (232 mg, 2.52 mmol) were
 20 reacted together in DCM (10 mL) at reflux overnight. The volatiles were removed under reduced pressure. Chromatography of the residue on SiO₂ (0-10% MeOH:DCM) afforded the title compound (767 mg, 82%). MS *m/z* 373.1 (M+H)⁺, 317.1 (M+H-*t*-butyl). ¹H NMR (300.1 MHz, DMSO) δ 12.80 (s, 0.6H), 7.59 (d, *J* = 7.2 Hz, 1H), 7.42 (d, *J* = 7.2 Hz, 2H), 4.09 (s, 1H), 3.30 (s, 2H), 3.16 (s, 2H), 2.35 (m, 4H), 1.38 (s, 9H).

25 Examples 2-30:

The following compounds were prepared in a manner analogous to that described in

Example 1:

Example No.	Name	MW	MS <i>m/z</i> (M+H) ⁺
2	4-{{[2-(3,4-dichlorophenyl)-2-piperazin-1-ylethoxy]methyl}-3-methoxy-2-naphthonitrile	470.40	470.2, 472.2

101431

- 13 -

3	3-methoxy-4-({2-piperazin-1-yl-2-[3-(trifluoromethoxy)phenyl]ethoxy}methyl)-2-naphthonitrile	485.51	486.4
4	3-methoxy-4-({2-piperazin-1-yl-2-[3-(trifluoromethyl)phenyl]ethoxy}methyl)-2-naphthonitrile	469.51	470.5
5	4-{{2-(2-chlorophenyl)-2-(4-methylpiperazin-1-yl)ethoxy}methyl}-3-methoxy-2-naphthonitrile	449.98	450.2
6	3-methoxy-4-({2-[3-(methylthio)phenyl]-2-piperazin-1-ylethoxy}methyl)-2-naphthonitrile	447.60	448.5
7	3-methoxy-4-{{2-(3-methoxyphenyl)-2-(4-methylpiperazin-1-yl)ethoxy}methyl}-2-naphthonitrile	445.57	446.6
8	4-{{2-(2,3-difluorophenyl)-2-piperazin-1-ylethoxy}methyl}-3-methoxy-2-naphthonitrile	437.49	438.4
9	4-{{2-(3,4-difluorophenyl)-2-piperazin-1-ylethoxy}methyl}-3-methoxy-2-naphthonitrile	437.49	438.2
10	4-{{2-(4-chlorophenyl)-2-piperazin-1-ylethoxy}methyl}-3-methoxy-2-naphthonitrile	435.96	436.4
11	4-{{2-(2-chlorophenyl)-2-piperazin-1-ylethoxy}methyl}-3-methoxy-2-naphthonitrile	435.96	436.3
12	4-{{2-(3-chlorophenyl)-2-piperazin-1-ylethoxy}methyl}-3-methoxy-2-naphthonitrile	435.96	436.2
13	4-{{2-(3-fluorophenyl)-2-(4-methylpiperazin-1-yl)ethoxy}methyl}-3-methoxy-2-naphthonitrile	433.53	434.6
14	4-{{2-(3-fluoro-4-methylphenyl)-2-piperazin-1-ylethoxy}methyl}-3-methoxy-2-naphthonitrile	433.53	434.5
15	4-{{2-(4-fluorophenyl)-2-(4-methylpiperazin-1-yl)ethoxy}methyl}-3-methoxy-2-naphthonitrile	433.53	434.5
16	4-{{2-(4-fluoro-2-methylphenyl)-2-piperazin-1-ylethoxy}methyl}-3-methoxy-2-naphthonitrile	433.53	434.5
17	3-methoxy-4-{{2-(3-methoxyphenyl)-2-piperazin-1-ylethoxy}methyl}-2-naphthonitrile	431.54	432.6
18	3-methoxy-4-{{2-(2-methoxyphenyl)-2-piperazin-1-ylethoxy}methyl}-2-naphthonitrile	431.54	432.6
19	3-methoxy-4-{{2-(4-methoxyphenyl)-2-piperazin-1-ylethoxy}methyl}-2-naphthonitrile	431.54	432.5
20	4-{{2-(4-fluorophenyl)-2-piperazin-1-ylethoxy}methyl}-3-methoxy-2-naphthonitrile	419.50	420.3
21	4-{{2-(3-fluorophenyl)-2-piperazin-1-ylethoxy}methyl}-3-methoxy-2-naphthonitrile	419.50	420.3
22	4-{{2-(2-fluorophenyl)-2-piperazin-1-ylethoxy}methyl}-3-methoxy-2-naphthonitrile	419.50	420.3
23	3-ethyl-4-{{2-(4-fluorophenyl)-2-piperazin-1-ylethoxy}methyl}-2-naphthonitrile	417.53	418.3

101431

2004 -04- 14

- 14 -

24	3-methoxy-4- {[2-(4-methylphenyl)-2-piperazin-1-ylethoxy]methyl}-2-naphthonitrile	415.54	416.5
25	3-methoxy-4- {[2-(3-methylphenyl)-2-piperazin-1-ylethoxy]methyl}-2-naphthonitrile	415.54	416.5
26	3-methoxy-4-[(2-phenyl-2-piperazin-1-ylethoxy)methyl]-2-naphthonitrile	401.51	402.5
27	4- {[2-(4-fluorophenyl)-2-piperazin-1-ylethoxy]methyl}-2-naphthonitrile	389.48	390.3
28	1-[2-[(4-fluoro-1-naphthyl)methoxy]-1-(4-fluorophenyl)ethyl]piperazine	382.45	383.2
29	1-[2-[(3-bromo-2-methoxy-5,6,7,8-tetrahydronaphthalen-1-yl)methoxy]-1-(4-fluorophenyl)ethyl]piperazine	477.42	477.2, 479.2

2004-04-14


2004-04-14

101431

- 15 -

What is claimed is:

1. A compound according to structural diagram I:



I

5

wherein:

R^1 and R^2 are independently selected from C_{1-6} alkyl or C_{1-6} alkenyl, or together with the N to which they are bound, form heterocycle containing 6-8 atoms or heterocycle substituted with moieties independently selected from hydrogen, halogen, C_{1-4} alkyl, C_{1-4} alkoxy or C_{1-4} alkyl substituted with 1, 2 or 3 halo moieties, amino, or amino substituted with C_{1-4} alkyl, C_{1-4} alkoxy, or C_{1-4} alkyl, substituted with 0, 1, 2 or 3 halo moieties; in vivo-hydrolysable precursors thereof, and pharmaceutically-acceptable salts thereof;

R^3 and R^4 are independently selected from hydrogen or C_{1-6} alkyl;

n is 0, 1 or 2;

Ar^1 is phenyl or phenyl substituted with moieties independently selected from hydrogen, halogen, C_{1-4} alkyl, C_{1-4} alkoxy or C_{1-4} alkyl substituted with 1, 2 or 3 halo moieties; in vivo-hydrolysable precursors thereof, and pharmaceutically-acceptable salts thereof; and

Ar^2 phenyl, naphthyl, tetralin, or phenyl, naphthyl or tetralin substituted with moieties independently selected from hydrogen, halogen, cyano, nitro, C_{1-4} alkyl, C_{1-4} alkoxy or C_{1-4} alkyl substituted with 1, 2 or 3 halo moieties; in vivo-hydrolysable precursors thereof, and pharmaceutically-acceptable salts thereof.

2. Pharmaceutically-acceptable salts of a compound according to Claim 1 made with an inorganic or organic acid which affords a physiologically-acceptable anion.

3. Pharmaceutically-acceptable salts according to Claim 2, wherein said inorganic or organic acid is selected from hydrochloric, hydrobromic, sulfuric, phosphoric, methanesulfonic, sulfamic,

para-toluenesulfonic, acetic, citric, lactic, tartaric, malonic, fumaric, ethanesulfonic, benzenesulfonic, cyclohexylsulfamic, salicyclic and quinic acids.

4. A pharmaceutical composition comprising a compound according to Claim 1, an in vivo-
5 hydrolysable precursor or a pharmaceutically-acceptable salt thereof and a pharmaceutically-acceptable carrier.
5. A method of treating a disease condition wherein antagonism of NK_1 receptors in combination with SRI activity is beneficial which method comprises administering to a warm-
10 blooded animal an effective amount of a compound according to Claim 1 or an in vivo-hydrolysable precursor or a pharmaceutically-acceptable salt thereof.
6. A method of treating a disease condition wherein antagonism of NK_1 receptors is beneficial which method comprises administering to a warm-blooded animal an effective amount
15 of a compound according to Claim 1 or an in vivo-hydrolysable precursor or a pharmaceutically-acceptable salt thereof.
7. A method of treating a disease condition wherein SRI activity is beneficial with method comprises administering to a warm-blooded animal an effective amount of a compound
20 according to Claim 1 or a in vivo-hydrolysable precursor or a pharmaceutically-acceptable salt thereof.
8. The use of a compound according to Claim 1 or an in vivo-hydrolysable precursor or a pharmaceutically-acceptable salt thereof in the preparation of a medicament for use in a disease
25 condition wherein antagonism of the NK_1 receptors or SRI activity is beneficial.
9. The use of a compound according to Claim 1 or an in vivo-hydrolysable precursor or a pharmaceutically-acceptable salt thereof in the preparation of a medicament for use in a disease
30 condition wherein antagonism of the NK_1 receptors and SRI activity is beneficial.

101431

- 17 -

10. A method for treating a disorder or condition selected from hypertension, depression in cancer patients, depression in Parkinson's patients, postmyocardial infarction depression, subsyndromal symptomatic depression, depression in infertile women, pediatric depression, major depression, single episode depression, recurrent depression, child abuse induced
- 5 depression, post partum depression, generalized anxiety disorder, agoraphobia, social phobia, simple phobias, posttraumatic stress syndrome, avoidant personality disorder, premature ejaculation, anorexia nervosa, bulimia nervosa, obesity, addictions to alcohol, cocaine, heroin, phenobarbital, nicotine or benzodiazepines; cluster headache, migraine, pain, Alzheimer's disease, obsessive-compulsive disorder, panic disorder, dementia, amnestic disorders, age-related
- 10 cognitive decline, dementia in Parkinson's disease, neuroleptic-induced parkinsonism, tardive dyskinesias, hyperprolactinaemia, vasospasm, cerebral vasculature vasospasm, cerebellar ataxia, gastrointestinal tract disorders, negative symptoms of schizophrenia, premenstrual syndrome, fibromyalgia syndrome, stress incontinence, Tourette's syndrome, trichotillomania, kleptomania, male impotence, attention deficit hyperactivity disorder, chronic paroxysmal hemicrania and
- 15 headache associated with vascular disorders in a mammal, wherein antagonism of the NK_1 receptors and SRI activity is beneficial, comprising administering an effective amount of a compound according to Claim 1 or a pharmaceutically-acceptable salt thereof effective in treating such disorder or condition.
- 20 11. The method according to any one of Claims 5, 6 or 7, wherein said compound is administered in combination with a pharmaceutically-acceptable carrier.


101431

- 18 -

A B S T R A C T

Title: ARYL GLYCINE ETHER DERIVATIVES AND THEIR USE

5 Compounds of the following formula



I

wherein R^1 , R^2 , n , Ar^1 and Ar^2 are as defined in the specification, in vivo-hydrolysable precursors
10 thereof, pharmaceutically-acceptable salts thereof, the use in therapy and pharmaceutical
compositions and methods of treatment using the same.